To comply with CMS and/or American Medical Association procedure code updates, effective Jan. 1, 2027, prior authorization will be needed for the following HCPCS code when administered in outpatient settings as treatment for cancer diagnosis.
Overall, we’re reducing the number of CPT® codes requiring prior authorization, but we may add prior authorization as new codes, such as these, become effective.
| HCPCS code | Description |
|---|---|
| J0594 | Injection, busulfan, 1 mg |
| J0643 | Injection, leucovorin calcium nos 1 mg |
| J0644 | Injection, leucovorin calcium avyxa 1 mg |
| J0896 | Injection, luspatercept-aamt, 0.25 mg |
| J1190 | Injection, dexrazoxane hydrochloride, per 250 mg |
| J1246 | Injection, dinutuximab, 0.1 mg |
| J2354 | Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg |
| J3315 | Injection, triptorelin pamoate, 3.75 mg |
| J3406 | Injection, omidubicel-onlv per therapeutic dose |
| J3489 | Injection, zoledronic acid, 1 mg |
| J7516 | Injection, cyclosporine, 250 mg |
This change affects UnitedHealthcare commercial plans and UnitedHealthcare® Medicare Advantage plans in all states, as well as UnitedHealthcare Community Plan and Individual Exchange plans, also referred to as UnitedHealthcare Individual & Family ACA Marketplace plans in the corresponding states:
CPT® is a registered trademark of the American Medical Association.
PCA-1-26-01731-Clinical-NN_0914202